Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation

• Autoři: MORENA M. Teresa de la; LEONARD David; TORGERSON Troy R.; CABRAL-MARQUES Otavio; SLATTER Mary; AGHAMOHAMMADI Asghar; CHANDRA Sharat; MURGUIA-FAVELA Luis; BONILLA Francisco A.; KANARIOU Maria; DAMRONGWATANASUK Rongras; KUO Caroline Y.; DVORAK Chistopher C.; MEYTS Isabelle; CHEN Karin; KOBRYNSKI Lisa; KAPOOR Neena; RICHTER Darko; DIGIOVANNI Daniela; DHALLA Fatima; FARMAKI Evangelia; SPECKMANN Carsten; ESPANOL Teresa; SHCHERBINA Anna; HANSON Imelda; LITZMAN Jiří; ROUTES John M.; WONG Melanie; FULEIHAN Ramsay; SENEVIRATNE Suranjith; SMALL Trudy N.; JANDA Ales; BEZRODNIK Liliana; SEGER Reinhard; RACCIO Andrea Gomez; EDGAR J. David M.; CHOU Janet; ABBOTT Jordan K.; MONTFRANS Joris van; GONZALEZ-GRANADO Luis Ignacio; BUNIN Nancy; KUTUKCULER Necil; GRAY Paul; SEMINARIO Gisela; PASIC Srdjan; AQUINO Victor; WYSOCKI Christian; ABOLHASSANI Hassan; DORSEY Morna; CUNNINGHAM-RUNDLES Charlotte; KNUTSEN Alan; SLEASMAN John; CARVALHO Beatriz Tavares Costa; CONDINO-NETO Antonio; GRUNEBAUM Eyal; CHAPEL Helen; OCHS Hans D.; FILIPOVICH Alexandra; COWAN Mort; GENNERY Andrew; CANT Andrew; NOTARANGELO Luigi D.; ROIFMAN Chaim M.
• Rok publikování: 2017
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: Journal of allergy and clinical immunology
• Fakulta / Pracoviště MU: Lékařská fakulta
• Doi: http://dx.doi.org/10.1016/j.jaci.2016.07.039
• Obor: Imunologie
• Klíčová slova: X-linked hyper-IgM syndrome; CD40 ligand; hematopoietic cell transplantation; defects in class-switch recombination; long-term outcomes; primary immunodeficiency; Karnofsky/Lansky scores
• Popis: Background: X-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compared with those seen in healthy subjects. Hematopoietic cell transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complications and might not be available for all patients. Objectives: We sought to collect data on the clinical presentation, treatment, and follow-up of a large sample of patients with XHIGM to (1) compare long-term overall survival and general well-being of patients treated with or without HCT along with clinical factors associated with mortality and (2) summarize clinical practice and risk factors in the subgroup of patients treated with HCT. Methods: Physicians caring for patients with primary immunodeficiency diseases were identified through the Jeffrey Modell Foundation, United States Immunodeficiency Network, Latin American Society for Immunodeficiency, and Primary Immune Deficiency Treatment Consortium. Data were collected with a Research Electronic Data Capture Web application. Survival from time of diagnosis or transplantation was estimated by using the Kaplan-Meier method compared with log-rank tests and modeled by using proportional hazards regression. Results: Twenty-eight clinical sites provided data on 189 patients given a diagnosis of XHIGM between 1964 and 2013; 176 had valid follow-up and vital status information. Sixty-seven (38%) patients received HCT. The average follow-up time was 8.5 +/- 7.2 years (range, 0.1-36.2 years). No difference in overall survival was observed between patients treated with or without HCT (P = .671). However, risk associated with HCT decreased for diagnosis years 1987-1995; the hazard ratio was significantly less than 1 for diagnosis years 1995-1999. Liver disease was a significant predictor of overall survival (hazard ratio, 4.9; 95% confidence limits, 2.2-10.8; P < .001). Among survivors, those treated with HCT had higher median Karnofsky/Lansky scores than those treated without HCT (P < .001). Among patients receiving HCT, 27 (40%) had graft-versus-host disease, and most deaths occurred within 1 year of transplantation. Conclusion: No difference in survival was observed between patients treated with or without HCT across all diagnosis years (1964-2013). However, survivors treated with HCT experienced somewhat greater well-being, and hazards associated with HCT decreased, reaching levels of significantly less risk in the late 1990s. Among patients treated with HCT, treatment at an early age is associated with improved survival. Optimism remains guarded as additional evidence accumulates.